Human immunodeficiency virus (HIV) protease inhibitors (Pis) have been used successfully in highly active anti-retroviral therapy (HAART) for HIV infection. Incorporation of HIV Pis in HAART causes profound and sustained suppression of viral replication, significantly reduces the morbidity and mortality, and prolongs the lifespan of patients with HIV infection. However, more than 50% of patients receiving HAART develop lipid abnormalities and diabetes, which are well-known risk factors for serious cardiovascular complications including endothelial dysfunction and atherosclerosis. Although the mechanism underlying HIV Pi-induced atherosclerosis remains to be fully identified, an increasing body of evidence suggests that multiple mechanisms may be involved, and individual Pis may have different effects on lipid metabolism. The development of other therapeutic interventions to counteract the HIV Pi-associated complications are especially urgent, and this development is the long-term objective of this application. Atherosclerosis is a chronic inflammatory disease and macrophages play a critical role in the initiation and progression of atherosclerotic lesions. Both inflammation and apoptosis are two major events in the pathophysiology of atherosclerosis. We have recently demonstrated that HIV Pis activate the unfolded protein response (UPR), induce apoptosis, and promote foam cell formation in macrophages. Berberine (BBR), an isoquinoline alkaloid isolated from many medicinal herbs, has significant anti-inflammatory activity and recently has been identified as a novel cholesterol-lowering drug. Our preliminary studies also indicate that BBR strongly inhibits HIV Pi-induced UPR activation, foam cell formation, and TNF-a and IL-6 release in macrophages. Based on these observations, we HYPOTHESIZE that BBR is able to prevent HIV Pi-induced atherosclerosis by inhibiting the UPR activation and the inflammatory response in macrophages.
Three specific aims are proposed to test the hypothesis.
Aim#1 : To elucidate the cellular/molecular mechanisms by which BBR inhibits HIV Pi-induced UPR activation in macrophages.
Aim#2 : To determine cellular/molecular mechanisms by which BBR inhibits HIV Pi-induced TNF-a and IL-6 synthesis in macrophages.
Aim#3 : To determine whether BBR is able to prevent the dyslipidemia and atherosclerosis induced by HIV Pis in an in vivo animal model. An increasing amount of attention has been paid to the use of complementary and alternative medicine (CAM) as a part of the treatment for HIV infection and the complications associated with HAART. Understanding the mechanisms by which BBR prevents HIV Pi- induced dyslipidemia and atherosclerosis is of great clinical importance. Completion of these specific aims will help identify and establish new therapeutic strategies for HIV infection.

Agency
National Institute of Health (NIH)
Institute
National Center for Complementary & Alternative Medicine (NCCAM)
Type
Research Project (R01)
Project #
5R01AT004148-04
Application #
7809454
Study Section
AIDS Discovery and Development of Therapeutics Study Section (ADDT)
Program Officer
Pontzer, Carol H
Project Start
2007-05-01
Project End
2012-04-30
Budget Start
2010-05-01
Budget End
2012-04-30
Support Year
4
Fiscal Year
2010
Total Cost
$355,517
Indirect Cost
Name
Virginia Commonwealth University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
105300446
City
Richmond
State
VA
Country
United States
Zip Code
23298
Liu, Runping; Zhang, Luyong; Yang, Jing et al. (2015) HIV Protease Inhibitors Sensitize Human Head and Neck Squamous Carcinoma Cells to Radiation by Activating Endoplasmic Reticulum Stress. PLoS One 10:e0125928
Gu, Shenghua; Cao, Bei; Sun, Runbin et al. (2015) A metabolomic and pharmacokinetic study on the mechanism underlying the lipid-lowering effect of orally administered berberine. Mol Biosyst 11:463-74
Zhang, Xiaoxuan; Cao, Risheng; Liu, Runping et al. (2014) Reduction of the HIV protease inhibitor-induced ER stress and inflammatory response by raltegravir in macrophages. PLoS One 9:e90856
Wu, Xudong; Li, Yunzhou; Peng, Kesong et al. (2014) HIV protease inhibitors in gut barrier dysfunction and liver injury. Curr Opin Pharmacol 19:61-6
Zhang, Xiaoxuan; Wang, Guangji; Gurley, Emily C et al. (2014) Flavonoid apigenin inhibits lipopolysaccharide-induced inflammatory response through multiple mechanisms in macrophages. PLoS One 9:e107072
Wang, Yun; Zhang, Luyong; Wu, Xudong et al. (2013) The role of CCAAT enhancer-binding protein homologous protein in human immunodeficiency virus protease-inhibitor-induced hepatic lipotoxicity in mice. Hepatology 57:1005-16
Zha, Weibin; Wang, Guangji; Xu, Weiren et al. (2013) Inhibition of P-glycoprotein by HIV protease inhibitors increases intracellular accumulation of berberine in murine and human macrophages. PLoS One 8:e54349
Zha, Beth S; Wan, Xiaoshan; Zhang, Xiaoxuan et al. (2013) HIV protease inhibitors disrupt lipid metabolism by activating endoplasmic reticulum stress and inhibiting autophagy activity in adipocytes. PLoS One 8:e59514
Zha, Weibin; Zha, Beth S; Zhou, Fang et al. (2012) The cellular pharmacokinetics of HIV protease inhibitors: current knowledge and future perspectives. Curr Drug Metab 13:1174-83
Zhou, Huiping (2011) HIV protease inhibitors induce endoplasmic reticulum stress and disrupt barrier integrity in intestinal epithelial cells. Methods Enzymol 490:107-19

Showing the most recent 10 out of 22 publications